AU2002217980A1 - Conjugates of glycosylated/galactosylated peptide - Google Patents
Conjugates of glycosylated/galactosylated peptideInfo
- Publication number
- AU2002217980A1 AU2002217980A1 AU2002217980A AU1798002A AU2002217980A1 AU 2002217980 A1 AU2002217980 A1 AU 2002217980A1 AU 2002217980 A AU2002217980 A AU 2002217980A AU 1798002 A AU1798002 A AU 1798002A AU 2002217980 A1 AU2002217980 A1 AU 2002217980A1
- Authority
- AU
- Australia
- Prior art keywords
- glycosylated
- conjugates
- galactosylated peptide
- galactosylated
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25013900P | 2000-12-01 | 2000-12-01 | |
US60/250,139 | 2000-12-01 | ||
PCT/US2001/044943 WO2002043771A2 (en) | 2000-12-01 | 2001-11-30 | Conjugates of glycosylated/galactosylated peptide |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2002217980A1 true AU2002217980A1 (en) | 2002-06-11 |
Family
ID=22946450
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2002217980A Abandoned AU2002217980A1 (en) | 2000-12-01 | 2001-11-30 | Conjugates of glycosylated/galactosylated peptide |
Country Status (8)
Country | Link |
---|---|
US (2) | US6906182B2 (en) |
EP (1) | EP1355672A2 (en) |
JP (1) | JP2004536027A (en) |
KR (1) | KR20030074637A (en) |
CN (1) | CN100406065C (en) |
AU (1) | AU2002217980A1 (en) |
CA (1) | CA2431839A1 (en) |
WO (1) | WO2002043771A2 (en) |
Families Citing this family (112)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030119724A1 (en) * | 1995-11-22 | 2003-06-26 | Ts`O Paul O.P. | Ligands to enhance cellular uptake of biomolecules |
WO2002092006A2 (en) | 2001-05-16 | 2002-11-21 | Micrologix Biotech, Inc. | Nucleic acid-based compounds and methods of use thereof |
US9657294B2 (en) | 2002-02-20 | 2017-05-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US9181551B2 (en) | 2002-02-20 | 2015-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
WO2004029221A2 (en) | 2002-09-27 | 2004-04-08 | The General Hospital Corporation | Microfluidic device for cell separation and uses thereof |
AU2004204763A1 (en) * | 2003-01-09 | 2004-07-29 | Arizeke Pharmaceuticals Inc. | Compositions and methods for targeted biological delivery of molecular carriers |
EP3034510A1 (en) * | 2004-04-30 | 2016-06-22 | Alnylam Pharmaceuticals Inc. | Oligonucleotides comprising a c5-modified pyrimidine |
WO2006104530A1 (en) * | 2005-03-28 | 2006-10-05 | Cell Works Therapeutics, Inc. | Therapeutics targeted to renal cells |
EP4026840A1 (en) * | 2005-07-18 | 2022-07-13 | Seagen Inc. | Beta-glucuronide-linker drug conjugates |
US8921102B2 (en) | 2005-07-29 | 2014-12-30 | Gpb Scientific, Llc | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
EP2019671B1 (en) | 2006-05-05 | 2014-09-24 | The Regents Of The University Of Michigan | Intermediates for the preparation of bivalent smac mimetics |
US20080050739A1 (en) | 2006-06-14 | 2008-02-28 | Roland Stoughton | Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats |
US8372584B2 (en) | 2006-06-14 | 2013-02-12 | The General Hospital Corporation | Rare cell analysis using sample splitting and DNA tags |
WO2007147074A2 (en) | 2006-06-14 | 2007-12-21 | Living Microsystems, Inc. | Use of highly parallel snp genotyping for fetal diagnosis |
US8137912B2 (en) | 2006-06-14 | 2012-03-20 | The General Hospital Corporation | Methods for the diagnosis of fetal abnormalities |
WO2008098788A2 (en) * | 2007-02-16 | 2008-08-21 | Ktb Tumorforschungsgesellschaft Mbh | Receptor and antigen targeted prodrug |
WO2009045536A2 (en) * | 2007-10-05 | 2009-04-09 | The University Of North Carolina At Chapel Hill | Receptor targeted oligonucleotides |
WO2009082607A2 (en) * | 2007-12-04 | 2009-07-02 | Alnylam Pharmaceuticals, Inc. | Targeting lipids |
EP2231194B1 (en) * | 2007-12-04 | 2017-02-22 | Alnylam Pharmaceuticals Inc. | Folate-irna conjugates |
WO2009126933A2 (en) * | 2008-04-11 | 2009-10-15 | Alnylam Pharmaceuticals, Inc. | Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components |
WO2010006237A2 (en) * | 2008-07-11 | 2010-01-14 | Alnylam Pharmaceuticals, Inc. | Phosphorothioate oligonucleotides non-nucleosidic phosphorothiotes as delivery agents for irna agents |
CA3069081C (en) | 2008-09-20 | 2023-05-23 | The Board Of Trustees Of The Leland Stanford Junior University | Noninvasive diagnosis of fetal aneuploidy by sequencing |
NZ592203A (en) | 2008-10-15 | 2013-01-25 | Isis Pharmaceuticals Inc | Modulation of factor 11 expression |
US8790916B2 (en) | 2009-05-14 | 2014-07-29 | Genestream, Inc. | Microfluidic method and system for isolating particles from biological fluid |
US8552163B2 (en) * | 2009-09-25 | 2013-10-08 | Johns Hopkins University | Liver-targeting agents and their synthesis |
EP3372684B1 (en) | 2010-08-24 | 2020-10-07 | Sirna Therapeutics, Inc. | Single-stranded rnai agents containing an internal, non-nucleic acid spacer |
EP3766975A1 (en) | 2010-10-29 | 2021-01-20 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina) |
EP3521451A1 (en) | 2010-11-17 | 2019-08-07 | Ionis Pharmaceuticals, Inc. | Modulation of alpha synuclein expression |
EP3453761A1 (en) | 2011-08-29 | 2019-03-13 | Ionis Pharmaceuticals, Inc. | Oligomer-conjugate complexes and their use |
WO2013126034A1 (en) * | 2012-02-22 | 2013-08-29 | Chemgenes Corporation | Synthesis of high purity dmt-c3-disulfide phosphoramidite |
CA2879693A1 (en) * | 2012-08-06 | 2014-02-13 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugated rna agents and process for their preparation |
WO2014179445A1 (en) | 2013-05-01 | 2014-11-06 | Regulus Therapeutics Inc. | Compounds and methods for enhanced cellular uptake |
IL284593B2 (en) | 2013-05-01 | 2023-02-01 | Ionis Pharmaceuticals Inc | Compositions and methods for modulating hbv and ttr expression |
JP2016518842A (en) | 2013-05-01 | 2016-06-30 | レグルス セラピューティクス インコーポレイテッド | MicroRNA compounds and methods of modulating miR-122 |
JP6694382B2 (en) | 2013-06-21 | 2020-05-13 | アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. | Compositions and methods for modulating target nucleic acids |
WO2015042447A1 (en) | 2013-09-20 | 2015-03-26 | Isis Pharmaceuticals, Inc. | Targeted therapeutic nucleosides and their use |
US11162096B2 (en) | 2013-10-14 | 2021-11-02 | Ionis Pharmaceuticals, Inc | Methods for modulating expression of C9ORF72 antisense transcript |
CA2929651A1 (en) * | 2013-11-06 | 2015-05-14 | Solstice Biologics, Ltd. | Polynucleotide constructs having disulfide groups |
WO2015143245A1 (en) | 2014-03-19 | 2015-09-24 | Isis Pharmaceuticals, Inc. | Methods for modulating ataxin 2 expression |
JP6902869B2 (en) | 2014-03-19 | 2021-07-14 | アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. | Composition for regulating the expression of ataxin 2 |
SG11201608109TA (en) | 2014-04-01 | 2016-10-28 | Ionis Pharmaceuticals Inc | Compositions for modulating sod-1 expression |
US9926556B2 (en) | 2014-04-28 | 2018-03-27 | Ionis Pharmaceuticals, Inc. | Linkage modified oligomeric compounds |
EP4223315A3 (en) | 2014-05-01 | 2023-08-23 | Ionis Pharmaceuticals, Inc. | Method for synthesis of reactive conjugate clusters |
RU2724527C2 (en) | 2014-05-01 | 2020-06-23 | Ионис Фармасьютикалз, Инк. | Compositions and methods for modulating growth hormone receptor expression |
EP3137605B1 (en) | 2014-05-01 | 2020-10-28 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating angiopoietin-like 3 expression |
CA2943705A1 (en) | 2014-05-01 | 2015-11-05 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating pkk expression |
BR112016022593B1 (en) | 2014-05-01 | 2022-04-26 | Ionis Pharmaceuticals, Inc | Oligomeric compounds, compositions comprising them, and uses thereof |
US10570169B2 (en) | 2014-05-22 | 2020-02-25 | Ionis Pharmaceuticals, Inc. | Conjugated antisense compounds and their use |
WO2016030863A1 (en) * | 2014-08-29 | 2016-03-03 | Glaxosmithkline Intellectual Property Development Limited | Compounds and methods for treating viral infections |
JOP20200092A1 (en) | 2014-11-10 | 2017-06-16 | Alnylam Pharmaceuticals Inc | HEPATITIS B VIRUS (HBV) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
US10793855B2 (en) | 2015-01-06 | 2020-10-06 | Ionis Pharmaceuticals, Inc. | Compositions for modulating expression of C9ORF72 antisense transcript |
US10538763B2 (en) | 2015-01-16 | 2020-01-21 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulation of DUX4 |
US11129844B2 (en) | 2015-03-03 | 2021-09-28 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating MECP2 expression |
RU2017137410A (en) | 2015-04-03 | 2019-05-06 | Ионис Фармасьютикалз, Инк. | CONNECTIONS AND METHODS OF MODELING THE EXPRESSION OF TMPRSS6 |
US10407678B2 (en) | 2015-04-16 | 2019-09-10 | Ionis Pharmaceuticals, Inc. | Compositions for modulating expression of C9ORF72 antisense transcript |
PE20180800A1 (en) | 2015-07-10 | 2018-05-09 | Ionis Pharmaceuticals Inc | DIACIGLYCEROL ACILTRANSFERASE 2 (DGAT2) MODULATORS |
TW201723176A (en) | 2015-09-24 | 2017-07-01 | Ionis製藥公司 | Modulators of KRAS expression |
US10533175B2 (en) | 2015-09-25 | 2020-01-14 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating Ataxin 3 expression |
WO2017079739A1 (en) | 2015-11-06 | 2017-05-11 | Ionis Pharmaceuticals, Inc. | MODULATING APOLIPOPROTEIN (a) EXPRESSION |
US20190046555A1 (en) | 2015-11-06 | 2019-02-14 | Ionis Pharmaceuticals, Inc. | Conjugated antisense compounds for use in therapy |
WO2017096395A1 (en) | 2015-12-04 | 2017-06-08 | Ionis Pharmaceuticals, Inc. | Methods of treating breast cancer |
CA3006599A1 (en) | 2016-01-05 | 2017-07-13 | Ionis Pharmaceuticals, Inc. | Methods for reducing lrrk2 expression |
CN113797348A (en) | 2016-03-07 | 2021-12-17 | 箭头药业股份有限公司 | Targeting ligands for therapeutic compounds |
WO2017161168A1 (en) | 2016-03-16 | 2017-09-21 | Ionis Pharmaceuticals, Inc. | Modulation of dyrk1b expression |
EP3429690A4 (en) | 2016-03-16 | 2019-10-23 | Ionis Pharmaceuticals, Inc. | Methods of modulating keap1 |
SG11201807827VA (en) | 2016-03-25 | 2018-10-30 | Seattle Genetics Inc | Process for the preparation of pegylated drug-linkers and intermediates thereof |
EP3471781A4 (en) | 2016-06-17 | 2020-05-06 | Ionis Pharmaceuticals, Inc. | Modulation of gys1 expression |
JP7197463B2 (en) | 2016-07-15 | 2022-12-27 | アイオーニス ファーマシューティカルズ, インコーポレーテッド | Compounds and methods for modulating SMN2 |
EP3506913A4 (en) | 2016-09-02 | 2020-06-10 | Arrowhead Pharmaceuticals, Inc. | Targeting ligands |
KR20190065341A (en) | 2016-10-06 | 2019-06-11 | 아이오니스 파마수티컬즈, 인코포레이티드 | Method of joining oligomeric compounds |
JOP20190104A1 (en) | 2016-11-10 | 2019-05-07 | Ionis Pharmaceuticals Inc | Compounds and methods for reducing atxn3 expression |
EP3548620A4 (en) | 2016-12-02 | 2020-07-22 | Cold Spring Harbor Laboratory | Modulation of lnc05 expression |
JP2020512312A (en) | 2017-03-24 | 2020-04-23 | シアトル ジェネティックス, インコーポレイテッド | Process for the preparation of glucuronide drug-linker and its intermediates |
JOP20190215A1 (en) | 2017-03-24 | 2019-09-19 | Ionis Pharmaceuticals Inc | Modulators of pcsk9 expression |
US11324820B2 (en) | 2017-04-18 | 2022-05-10 | Alnylam Pharmaceuticals, Inc. | Methods for the treatment of subjects having a hepatitis b virus (HBV) infection |
WO2019006455A1 (en) | 2017-06-30 | 2019-01-03 | Solstice Biologics, Ltd. | Chiral phosphoramidite auxiliaries and methods of their use |
AU2018318231A1 (en) | 2017-08-18 | 2020-02-13 | Ionis Pharmaceuticals, Inc. | Modulation of the notch signaling pathway for treatment of respiratory disorders |
WO2019051173A1 (en) | 2017-09-08 | 2019-03-14 | Ionis Pharmaceuticals, Inc. | Modulators of smad7 expression |
TWI809004B (en) | 2017-11-09 | 2023-07-21 | 美商Ionis製藥公司 | Compounds and methods for reducing snca expression |
WO2019126641A2 (en) | 2017-12-21 | 2019-06-27 | Ionis Pharmaceuticals, Inc. | Modulation of frataxin expression |
MA51645A (en) | 2018-01-15 | 2020-11-25 | Ionis Pharmaceuticals Inc | DNM2 EXPRESSION MODULATORS |
AU2019218987A1 (en) | 2018-02-12 | 2020-07-23 | Ionis Pharmaceuticals, Inc. | Modified compounds and uses thereof |
US11241451B2 (en) | 2018-03-02 | 2022-02-08 | Ionis Pharmaceuticals, Inc. | Modulators of IRF4 expression |
EP3759127A4 (en) | 2018-03-02 | 2022-03-30 | Ionis Pharmaceuticals, Inc. | Compounds and methods for the modulation of amyloid-beta precursor protein |
WO2019183440A1 (en) | 2018-03-22 | 2019-09-26 | Ionis Pharmaceuticals, Inc. | Methods for modulating fmr1 expression |
EP3768708A4 (en) * | 2018-03-23 | 2022-08-03 | The Regents of the University of California | Methods and compounds for targeted autophagy |
KR20200141481A (en) | 2018-04-11 | 2020-12-18 | 아이오니스 파마수티컬즈, 인코포레이티드 | Regulator of EZH2 expression |
AU2019266307A1 (en) | 2018-05-09 | 2020-11-19 | Ionis Pharmaceuticals, Inc. | Compounds and methods for reducing ATXN3 expression |
BR112020020957B1 (en) | 2018-05-09 | 2022-05-10 | Ionis Pharmaceuticals, Inc | Oligomeric compounds, population and pharmaceutical composition thereof and their uses |
JP2021526823A (en) | 2018-06-14 | 2021-10-11 | アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. | Compounds and methods for increasing STMN2 expression |
CN112400019B (en) | 2018-06-27 | 2024-05-07 | Ionis制药公司 | Compounds and methods for reducing LRRK2 expression |
AR115847A1 (en) | 2018-07-25 | 2021-03-03 | Ionis Pharmaceuticals Inc | COMPOUNDS AND METHODS TO REDUCE THE EXPRESSION OF ATXN2 |
EP3833397A4 (en) | 2018-08-08 | 2023-06-14 | Arcturus Therapeutics, Inc. | Compositions and agents against nonalcoholic steatohepatitis |
MX2021001056A (en) | 2018-08-13 | 2021-04-12 | Alnylam Pharmaceuticals Inc | HEPATITIS B VIRUS (HBV) dsRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF. |
TW202023573A (en) | 2018-09-19 | 2020-07-01 | 美商Ionis製藥公司 | Modulators of pnpla3 expression |
TW202028222A (en) | 2018-11-14 | 2020-08-01 | 美商Ionis製藥公司 | Modulators of foxp3 expression |
JOP20210108A1 (en) | 2018-11-15 | 2023-01-30 | Ionis Pharmaceuticals Inc | Modulators of irf5 expression |
AU2020216444A1 (en) | 2019-01-31 | 2021-07-29 | Ionis Pharmaceuticals, Inc. | Modulators of YAP1 expression |
EP3931328A4 (en) | 2019-02-27 | 2023-09-13 | Ionis Pharmaceuticals, Inc. | Modulators of malat1 expression |
PE20220284A1 (en) | 2019-03-29 | 2022-02-25 | Ionis Pharmaceuticals Inc | COMPOUNDS AND METHODS TO MODULAR UBE3A-ATS |
EP3956450A4 (en) | 2019-07-26 | 2022-11-16 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating gfap |
WO2021074772A1 (en) | 2019-10-14 | 2021-04-22 | Astrazeneca Ab | Modulators of pnpla3 expression |
KR20220148230A (en) | 2020-02-28 | 2022-11-04 | 아이오니스 파마수티컬즈, 인코포레이티드 | Compounds and methods for modulating SMN2 |
WO2021222768A2 (en) | 2020-05-01 | 2021-11-04 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating atxn1 |
TW202214301A (en) * | 2020-06-16 | 2022-04-16 | 大陸商上海拓界生物醫藥科技有限公司 | Carbohydrate molecular cluster and preparation method and medical use thereof |
WO2022006134A2 (en) | 2020-06-29 | 2022-01-06 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating plp1 |
KR20230108728A (en) | 2020-11-18 | 2023-07-18 | 아이오니스 파마수티컬즈, 인코포레이티드 | Compounds and methods for modulating angiotensinogen expression |
CA3223192A1 (en) | 2021-06-18 | 2022-12-22 | Ionis Pharmaceuticals, Inc. | Compounds and methods for reducing ifnar1 expression |
WO2023086295A2 (en) | 2021-11-10 | 2023-05-19 | University Of Rochester | Antisense oligonucleotides for modifying protein expression |
WO2023086292A2 (en) | 2021-11-10 | 2023-05-19 | University Of Rochester | Gata4-targeted therapeutics for treatment of cardiac hypertrophy |
WO2023178144A2 (en) | 2022-03-16 | 2023-09-21 | Empirico Inc. | Galnac compositions for improving sirna bioavailability |
WO2024050261A1 (en) | 2022-08-29 | 2024-03-07 | University Of Rochester | Antisense oligonucleotide-based anti-fibrotic therapeutics |
Family Cites Families (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4415732A (en) | 1981-03-27 | 1983-11-15 | University Patents, Inc. | Phosphoramidite compounds and processes |
US4671958A (en) | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
DE3329892A1 (en) | 1983-08-18 | 1985-03-07 | Köster, Hubert, Prof. Dr., 2000 Hamburg | METHOD FOR PRODUCING OLIGONUCLEOTIDES |
US4680338A (en) | 1985-10-17 | 1987-07-14 | Immunomedics, Inc. | Bifunctional linker |
US5141739A (en) | 1986-07-03 | 1992-08-25 | Advanced Magnetics, Inc. | Delivery of x-ray contrast agents using receptor mediated endocytosis |
US4770183A (en) | 1986-07-03 | 1988-09-13 | Advanced Magnetics Incorporated | Biologically degradable superparamagnetic particles for use as nuclear magnetic resonance imaging agents |
US5284646A (en) | 1986-07-03 | 1994-02-08 | Advanced Magnetics Inc. | Hepatocyte specific receptor mediated endocytosis type magnetic resonance imaging contrast agents |
US4827945A (en) | 1986-07-03 | 1989-05-09 | Advanced Magnetics, Incorporated | Biologically degradable superparamagnetic materials for use in clinical applications |
US5248492A (en) | 1986-07-03 | 1993-09-28 | Advanced Magnetics, Inc. | Low molecular weight carbohydrates as additives to stabilize metal oxide compositions |
US5336506A (en) | 1986-07-03 | 1994-08-09 | Advanced Magnetics Inc. | Targeting of therapeutic agents using polysaccharides |
US5352432A (en) | 1986-07-03 | 1994-10-04 | Advanced Magnetics, Inc. | Hepatocyte specific composition and their use as diagnostic imaging agents |
US5478576A (en) | 1986-07-03 | 1995-12-26 | Advanced Magnetics, Inc. | Arabinogalactan derivatives and uses thereof |
US5342607A (en) | 1986-07-03 | 1994-08-30 | Advanced Magnetics, Inc. | Receptor mediated endocytosis type magnetic resonance imaging contrast agents |
US5490991A (en) | 1986-07-03 | 1996-02-13 | Advanced Magnetics, Inc. | Directed delivery of radioprotectants using a receptor specific carrier |
US5679323A (en) | 1986-07-03 | 1997-10-21 | Advanced Magnetics, Inc. | Hepatocyte-specific receptor-mediated endocytosis-type compositions |
US5554386A (en) | 1986-07-03 | 1996-09-10 | Advanced Magnetics, Inc. | Delivery of therapeutic agents to receptors using polysaccharides |
IN165717B (en) | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
US6005094A (en) | 1986-10-28 | 1999-12-21 | Genta Incorporated | Oligonucleotide analogues having improved stability at acid pH |
US5773435A (en) | 1987-08-04 | 1998-06-30 | Bristol-Myers Squibb Company | Prodrugs for β-lactamase and uses thereof |
US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
US4952394A (en) | 1987-11-23 | 1990-08-28 | Bristol-Myers Company | Drug-monoclonal antibody conjugates |
US5141648A (en) | 1987-12-02 | 1992-08-25 | Neorx Corporation | Methods for isolating compounds using cleavable linker bound matrices |
US5017693A (en) | 1987-12-02 | 1991-05-21 | Neorx Corporation | Methods for introducing a sulfhydryl amino or hydroxyl groups to a compound |
US5563250A (en) | 1987-12-02 | 1996-10-08 | Neorx Corporation | Cleavable conjugates for the delivery and release of agents in native form |
FI102355B1 (en) | 1988-02-11 | 1998-11-30 | Bristol Myers Squibb Co | A method for preparing anthracycline immunoconjugates having a linking spacer |
US5094849A (en) | 1988-08-08 | 1992-03-10 | Eli Lilly And Company | Cytotoxic antibody conjugates of hydrazide derivatized vinca analogs via simple organic linkers |
US5006652A (en) | 1988-08-08 | 1991-04-09 | Eli Lilly And Company | Intermediates for antibody-vinca drug conjugates |
US5028697A (en) | 1988-08-08 | 1991-07-02 | Eli Lilly And Company | Cytotoxic antibody conjugates of hydrazide derivatized methotrexate analogs via simple organic linkers |
US5144012A (en) | 1988-08-08 | 1992-09-01 | Eli Lilly And Company | Cytotoxic drug conjugates |
US5169933A (en) | 1988-08-15 | 1992-12-08 | Neorx Corporation | Covalently-linked complexes and methods for enhanced cytotoxicity and imaging |
US5010176A (en) | 1988-11-10 | 1991-04-23 | Eli Lilly And Company | Antibody-drug conjugates |
US5433955A (en) | 1989-01-23 | 1995-07-18 | Akzo N.V. | Site specific in vivo activation of therapeutic drugs |
US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
US5308604A (en) | 1989-04-19 | 1994-05-03 | Deutsches Krebsforschungsinstitut | Conjugates for tumor localization and/or tumor therapy |
US5280113A (en) | 1989-08-16 | 1994-01-18 | Monsanto Company | Method for producing synthetic N-linked glycoconjugates |
US5116944A (en) | 1989-12-29 | 1992-05-26 | Neorx Corporation | Conjugates having improved characteristics for in vivo administration |
US5677440A (en) | 1990-07-16 | 1997-10-14 | Howard Florey Institute Of Experimental Physiology And Medicine | Oligonucleotide-polyamide conjugates |
US5149794A (en) | 1990-11-01 | 1992-09-22 | State Of Oregon | Covalent lipid-drug conjugates for drug targeting |
US5543390A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
EP0513332A4 (en) | 1990-11-14 | 1993-03-17 | Cargill, Incorporated | Conjugates of poly(vinylsaccharide) with proteins for the stabilization of proteins |
US5495006A (en) | 1991-09-27 | 1996-02-27 | Allelix Biopharmaceuticals, Inc. | Antiviral polynucleotide conjugates |
US5700922A (en) | 1991-12-24 | 1997-12-23 | Isis Pharmaceuticals, Inc. | PNA-DNA-PNA chimeric macromolecules |
US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
US5393737A (en) | 1992-08-20 | 1995-02-28 | Health Research, Inc. | Cytotoxic drug conjugates for treatment of neoplastic diseases |
US5574142A (en) | 1992-12-15 | 1996-11-12 | Microprobe Corporation | Peptide linkers for improved oligonucleotide delivery |
US5556623A (en) | 1993-03-30 | 1996-09-17 | Eli Lilly And Company | Antibody-drug conjugates |
US6413949B1 (en) | 1995-06-07 | 2002-07-02 | D-Pharm, Ltd. | Prodrugs with enhanced penetration into cells |
US5681811A (en) | 1993-05-10 | 1997-10-28 | Protein Delivery, Inc. | Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same |
US5457187A (en) * | 1993-12-08 | 1995-10-10 | Board Of Regents University Of Nebraska | Oligonucleotides containing 5-fluorouracil |
US6037329A (en) | 1994-03-15 | 2000-03-14 | Selective Genetics, Inc. | Compositions containing nucleic acids and ligands for therapeutic treatment |
US5589334A (en) | 1994-06-03 | 1996-12-31 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecule which codes for a tumor rejection antigen precursor which is processed to an antigen presented by HLA-B44, and uses thereof |
US5612474A (en) | 1994-06-30 | 1997-03-18 | Eli Lilly And Company | Acid labile immunoconjugate intermediates |
US5872007A (en) | 1995-02-17 | 1999-02-16 | Hybridon, Inc. | CAPL-specific oligonucleotides and methods of inhibiting metastatic cancer |
WO1996040662A2 (en) | 1995-06-07 | 1996-12-19 | Cellpro, Incorporated | Aminooxy-containing linker compounds and their application in conjugates |
US5646298A (en) | 1995-06-07 | 1997-07-08 | Procoron, Inc. | Cyclopropylindole prodrugs |
CN1120707C (en) * | 1995-11-22 | 2003-09-10 | 约翰斯·霍普金斯大学 | Ligands to enhance cellular uptake of biomolecules |
US5700921A (en) | 1995-11-27 | 1997-12-23 | Vector Laboratories | Labeling nucleic acids |
US5981507A (en) | 1995-12-14 | 1999-11-09 | Advanced Magnetics, Inc. | Polymeric carriers linked to nucleotide analogues via a phosphoramide bond |
US5880097A (en) | 1996-01-04 | 1999-03-09 | Terrapin Techologies, Inc. | Tethered prodrugs |
AU723678B2 (en) | 1996-03-18 | 2000-08-31 | Molecular Biology Resources, Inc. | Target nucleic acid sequence amplification |
NZ330360A (en) | 1997-06-02 | 1999-03-29 | Hoffmann La Roche | 5'-deoxy-cytidine derivatives, their manufacture and use as antitumoral agents |
EP0884327B1 (en) | 1997-06-11 | 2001-03-14 | The School Of Pharmacy, University Of London | Dendritic lysine-based polypeptides for targeted drug delivery |
US5929049A (en) | 1997-08-08 | 1999-07-27 | Dade Behring Marburg Gmbh | Polysaccharide conjugates of biomolecules |
US6187335B1 (en) | 1997-12-31 | 2001-02-13 | Orasomal Technologies, Inc. | Polymerizable fatty acids, phospholipids and polymerized liposomes therefrom |
US6030997A (en) | 1998-01-21 | 2000-02-29 | Eilat; Eran | Acid labile prodrugs |
US6005098A (en) | 1998-02-06 | 1999-12-21 | Hoffmann-La Roche Inc. | 5'deoxycytidine derivatives |
US6409990B1 (en) | 1999-05-14 | 2002-06-25 | The Regents Of The University Of California | Macromolecular carrier for drug and diagnostic agent delivery |
US6342485B1 (en) * | 1999-10-15 | 2002-01-29 | William H. Gmeiner | Synergistic compositions useful as anti-tumor agents |
AU1352701A (en) | 1999-10-29 | 2001-05-14 | University Of Utah Research Foundation | An activated-thiol polymer for drug delivery |
-
2001
- 2001-11-30 WO PCT/US2001/044943 patent/WO2002043771A2/en active Application Filing
- 2001-11-30 US US09/998,497 patent/US6906182B2/en not_active Expired - Fee Related
- 2001-11-30 EP EP01998366A patent/EP1355672A2/en not_active Withdrawn
- 2001-11-30 CN CNB018222455A patent/CN100406065C/en not_active Expired - Fee Related
- 2001-11-30 CA CA002431839A patent/CA2431839A1/en not_active Abandoned
- 2001-11-30 AU AU2002217980A patent/AU2002217980A1/en not_active Abandoned
- 2001-11-30 JP JP2002545741A patent/JP2004536027A/en active Pending
- 2001-11-30 KR KR10-2003-7007358A patent/KR20030074637A/en active IP Right Grant
-
2005
- 2005-06-13 US US11/152,135 patent/US7262177B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1489477A (en) | 2004-04-14 |
US7262177B2 (en) | 2007-08-28 |
EP1355672A2 (en) | 2003-10-29 |
WO2002043771A9 (en) | 2004-04-29 |
CN100406065C (en) | 2008-07-30 |
KR20030074637A (en) | 2003-09-19 |
WO2002043771A3 (en) | 2003-08-28 |
CA2431839A1 (en) | 2002-06-06 |
US20050250679A1 (en) | 2005-11-10 |
US6906182B2 (en) | 2005-06-14 |
WO2002043771A2 (en) | 2002-06-06 |
US20030032584A1 (en) | 2003-02-13 |
JP2004536027A (en) | 2004-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002217980A1 (en) | Conjugates of glycosylated/galactosylated peptide | |
AU2001294192A1 (en) | Solid preparations | |
AU4439201A (en) | Whipstock asssembly | |
AU2001276737A1 (en) | Protein injection preparations | |
AU2000269903A1 (en) | Mechanical connection of panels | |
AU1951201A (en) | Peptide antigens | |
AU2001250212A1 (en) | Rhamm peptide conjugates | |
AU2001242479A1 (en) | Proliposomal encapsulated preparations | |
AU2001284418A1 (en) | Novel polypeptide | |
AU2002243314A1 (en) | Immunogenic cancer peptides and uses thereof | |
AU2002303259A1 (en) | Peptides incorporating chemoselective functionalities | |
EP1385556A4 (en) | Gastrin-receptor-avid peptide conjugates | |
AU2001288102A1 (en) | Solid preparations | |
AU2001288220A1 (en) | Hyperglycosylated polypeptides | |
AU2001272427A1 (en) | Solid preparations | |
AU2001282521A1 (en) | OCT preparations | |
AU2001296389A1 (en) | Stable peptide formulations | |
AU2002239747A1 (en) | Cystoskeleton-associated proteins | |
AU2001244863A1 (en) | Apoptin-associating protein | |
AU2001278975A1 (en) | Alpha-conotoxin peptides | |
AU2002215145A1 (en) | Dual orientation connector | |
AU2002256425A1 (en) | Gastrin-receptor-avid peptide conjugates | |
AU2001271843A1 (en) | Gtp-binding proteins | |
AU2001241044A1 (en) | Mitf-associated proteins | |
AU2001278777A1 (en) | Irap-binding protein |